Psychedelics for Patients With Cancer: A Comprehensive Literature Review
Annals of Pharmacotherapy · 2023-09 · 57 (9) · 1062-1075
DOI: 10.1177/10600280221144055 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annals of Pharmacotherapy, online erschienen am 12.01.2023. Verfasst von C Michael White und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, CT, USA. Hauptthemen laut MEDLINE: Hallucinogens, N-Methyl-3,4-methylenedioxyamphetamine, Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Objective
To assess the role of psychedelics in the treatment of anxiety or depression among patients with cancer. Data Sources: PubMed search from inception to March 11, 2022, using the terms anxiety, depression, psychedelics, psilocybin, lysergic acid, methylenedioxymethamphetamine, or ayahuasca. Study Selection and Data Extraction: Studies assessing patients with cancer receiving psychedelics for the treatment of anxiety or depression. Data Synthesis: Five unique randomized, double-blind, placebo-controlled trials were conducted. Significant reductions were found in 2 trials with 2 anxiety scales (State-Trait Anxiety Inventory–State, State-Trait Anxiety Inventory–Trait) and in 1 trial with 2 additional anxiety scales (Hamilton Rating Scale–Anxiety, Hospital Anxiety and Depression Scale–Anxiety). Significant reductions were found in 2 trials in 2 depression scales (Hospital Anxiety and Depression Scale–Depression, Beck Depression Inventory) and in 1 trial with an additional depression scale (Hamilton Rating Scale–Depression). Two studies assessed for clinically relevant reductions in anxiety and depression scores, and they occurred much more commonly in psychedelic-treated patients than those given placebo. Relevance to Patient Care and Clinical Practice: There is a new potential option for treating patients with anxiety and depression along with cancer, which is important given the generally lackluster benefits with traditional antidepressants. Only a few sessions may also provide benefits extending out for 6 to 12 months and possibly beyond that. However, the studies were small, had many methodological limitations, and there were increases in blood pressure and heart rate.
Conclusions
Psychedelics have a unique mechanism of action that might be well suited for treating anxiety and depression associated with cancer. This offers new promise for patients who are not being sufficiently treated with current antianxiety or antidepressant medications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, CT, USA.
ORCID-Profile: C Michael White
Zitieren
APA
White, C. M., Weisman, N., & Dalo, J. (2023). Psychedelics for Patients With Cancer: A Comprehensive Literature Review. Annals of Pharmacotherapy, 57(9), 1062-1075. https://doi.org/10.1177/10600280221144055
Vancouver
White CM, Weisman N, Dalo J. Psychedelics for Patients With Cancer: A Comprehensive Literature Review. Annals of Pharmacotherapy. 2023;57(9):1062-1075. doi:10.1177/10600280221144055
BibTeX
@article{White2023,
author = {White, C Michael and Weisman, Nissen and Dalo, Joseph},
title = {Psychedelics for Patients With Cancer: A Comprehensive Literature Review},
journal = {Annals of Pharmacotherapy},
year = {2023},
volume = {57},
number = {9},
pages = {1062--1075},
doi = {10.1177/10600280221144055}
}
EUVIMED